Motivation for treatment of HCV infection among drug users;Motivácia na liečbu hepatitídy C u uživatel'ov psychoaktívnych látok

Adiktologie

Volumn 11, Issue 3, 2011, Pages 142-146

  Slezakova S ^a   Okruhlica, L ^a  

^a Centre for Treatment of Drug Dependencies   (Slovakia)

Author keywords

Hepatitis C; Injecting drug users; Motivation; Treatment

Indexed keywords

EID: 83655165142     PISSN: 12133841     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Cournot, M., Glibert, A , Castel, F., Druart, F., Imani, K., Lauwers-Cances, V., & Morin, T. (2004). Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol. Clin. Biol., 28(6-7 Pt 1). 533-539. (Pubitemid 38917484)
2. Dalgard, O. (2005). Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clmical Infectious Diseases, 40, Suppl. 5, 336-338.
3. EMCDDA (2009). Annual Report 2009. Lisabon: EMCDDA.
4. Edlin, B. R., Kresina T. F., Raymond D. B. et al. (2005). Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases, 40 (Suppl.), 276-85.
5. Gazdík, F., Gazdíkova, K.. Laktis, K., Okruhlica. L., Fejdiova, K., Hanis, D., Pijak, M. R., Wsolova, L., Kajaba, I.. & Krátky, A. (2009). High Virologie sustained response for former ypung intravenous drug users with chronic hepatitis C treated by pegylated interferon-a plus ribavirin. Bratislavske lekárske listy, 110(2), 77-84.
6. Grebely, J., Knight, E. Ngai, T., Genoway, K. A.. Raffa, J. D., Storms, M., Gallagher, L., Krajden, M., Dore, G. J., Duncan, F., 6 Conway, B. (2010). Reinfection with hepatitis C virus following sustained virological response in injection drug users. Journal of Gastroenterology and Hepatology, 25,1281-1284.
7. Miller, W. R., Rollnick, S. (2003). Motivaèní rozhovory. Tišnov: Sdružení SCAN.
8. Morrill, J. A., Shrestha, M., & Grant, R. W. (2005). Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Journal of General Internal Medicine. 20 (8), 754-758. (Pubitemid 41141009)
9. Moussalli, J., Melin, P., Wartelle-Bladou. C.. & Lang. J. P. (2007). Management of hepatitis C among drug user patients. Gastroenterol. Clin. Biol., 31(8-9 Pt 3), 51-55.
10. Moussalli, J., Delaquaize, H., Boubilley, D., Lhomme, J. P., Merleau-Ponty, J., Sabot, D., Kerever, A., Valleur, M., & Poynard, T. (2010). Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre Gastroenterol. Res. Pract., pii: 261472. Epub 2010 Jul. 18.
11. Munoz-Plazaa, C. E., Straussa, S., Astone-Twerella, J., Des Jarlaisb, D., Gwadza, M., Hagana, H., Osbornea, A., & Rosenbluma, A. (2008). Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the US. International Journal of Drug Pohcy, 19, 71-78.
12. Robaeys, G., Van Vlierberghe, H., Mathed, C Van Ranst. M., Bruckers, L., Buntinx, F., & BASL Steering Committee, Benelux Study Group (2006). Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur. J. Gastroenterol. Hepatol.. 18(2). 159-166. (Pubitemid 43361601)
13. Tejová, M., Coufalová, J., Slezáková S., 5 Okruhlica, L. (2009). Finanèná odmena ako silný motivátor v lieèbe závislostí od tabaku. Alkoholizmus a drogové závislosti, 44, 273-284.